Evaluation of malignant features in oligodendroglial tumors

Clinical Neuropathology

Volumn 18, Issue 2, 1999, Pages 61-73

  Saito, A ^a,b   Nakazato, Y ^a  

^a GUNMA UNIVERSITY   (Japan)

^b UNIVERSITY OF THE RYUKYUS SCHOOL OF MEDICINE   (Japan)

Author keywords

Immunohistochemistry; Malignancy; Oligo astrocytoma; Oligodendroglioma; Pathology

Indexed keywords

GLIAL FIBRILLARY ACIDIC PROTEIN;

ARTICLE; ASTROCYTOMA; BRAIN TUMOR; CANCER GRADING; CELL PROLIFERATION; ENDOTHELIUM CELL; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALIGNANT NEOPLASTIC DISEASE; MALIGNANT TRANSFORMATION; MITOSIS INDEX; OLIGODENDROGLIA; PRIORITY JOURNAL;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL; BRAIN NEOPLASMS; EVALUATION STUDIES; FEMALE; GLIOMA; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OLIGODENDROGLIOMA; STAINING AND LABELING; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0033017664     PISSN: 07225091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Biernat W, Kleihues P, Yonekawa Y, Oligaki H 1997 Amplification and overexpression of MDM2 in primary (de novo) glioblastomas. J Neuropathol Exp Neurol 56: 180-185
2. Burger PC, Rawlings CE, Cox EB, McIendon RE, Schold Jr SC, Bullard DE 1987 Clinicopathologic correlations in the oligodendroglioma. Cancer 59: 1345-13523
3. Burger PC, Scheithauer BW 1994 Tumors of the central nervous system. Atlas of tumor pathology, 3rd series. Armed Forces Institute of Pathology, Washington, DC, pp 107-120
4. Cairncross JG, Macdonald DR, Ramsay DA 1992 Ag gressive oligodendroglioma: A chemosensitive tumor. Neurosurgery 31: 78-82
5. Coons SW, Johnson PC 1995 MIB1/Ki-67 labeling index predicts patient survival for oligodendroglial tumors. J Neuropathol Exp Neurol 54: 440
6. Coons SW, Johnson PC, Scheithauer BW, Yates AJ, Pearl DK 1997 Improving diagnostic accuracy and interobserver concordance in the classification and grading of primary gliomas. Cancer 79: 1381-1393
7. Daumas-Duport C, Scheithauer BW, O'Fallon J, Kelly P 1988 Grading of astrocytomas. A simple and reproducible method. Cancer 62: 2152-2165
8. Deimling A von, Louis DN, Wiestler OD 1995 Molecular pathways in the formation of gliomas. Glia 15: 328-338
9. De la Monte SM 1989 Uniform lineage of oligodendrogliomas. Am J Pathol 135: 529-540
10. Dutto I, Bosone P, Cavalla P, Schiffer D 1997 Oligodendroglioma: prognostic factors in a series of 102 cases. Clin Neuropathol 16: 154
11. Heegaard S, Sommer HM, Broholm H, Broendstrup O 1995 Proliferating cell nuclear antigen and Ki-67 immunohistochemistry of oligodendrogliomas with specitil reference to prognosis. Cancer 76: 1809-1813
12. Herpers MJHM, Budha H 1984 Glial fibrillary acidic protein (GFAP) in oligodendroglial tumors: Gliofibrillary oligodendroglioma and transitional oligoastrocytoma as subtypes of oligodendroglioma. Acta Neuropathol (Berl) 64: 265-272
13. Karamitopoulou E, Perentes E, Diamantis I, Maraziotis T 1994 Ki-67 immunoreactivity in human central nervous system tumors: a study with MIB1 monoclonal antibody on archival material. Acta Neuropathol (Berl) 87: 47-54
14. Kim L, Hochberg FH, Thornton AF, Harsh GR, Patel H, Finkelstein D, Louis DN 1996 Procarbazine, lomustine, and vincristine (PCV) chemotherapy for Grade III and Grade IV oligoastrocytomas. J Neurosurg 85: 602-607
15. Kleihues P, Burger PC, Scheithauer BW 1993 Histological Typing of Tumours of the Central Nervous System, 2nd edn. Springer, Berlin
16. Kraus JA, Koopmann J, Kaskel P, Maintz D, Brandner S, Schramm J, Louis DN, Wiestler OD, van Deimling A 1995 Shared allelic losses on chromosomes 1p and 19q suggest a common origin of oligodendroglioma and oligoastrocytoma. J Neuropathol Exp Neurol 54: 91-95
17. Kros JM, Troost D, van Eden CC, van der Werf AJM, Uylings HBM 1988 Oligodendroglioma. A comparison of two grading systems. Cancer 61: 2251-2259
18. Kros JM, van Eden CG, Stefanko SZ, Waayer-van Batenburg M, van der Kwast TH 1990 Prognostic implications of glial fibrillary acidic protein containing cell types in oligodendrogliomas. Cancer 66: 1204-1212
19. Kros JM, de Jong AAW, van der Kwast TH 1992 Ultra-structural characterization of transitional cells in oligodendrogliomas. J Neuropathol Exp Neurol 51: 186-193
20. Kros JM, Godshalk JJCJ, Krishnadath KK, van Eden CG 1993 Expression of p53 in oligodendrogliomas. J Pathol 171: 285-290
21. Kros JM, Hop WCJ, Godshalk JJCJ, Krishnadath KK 1996a Prognostic value of the proliferation-related antigen Ki-67 in oligodendroglioma. Cancer 78: 1107-1113
22. Kros JM, Schouten WCD, Janssen PJA, van der Kwast TH 1996b Proliferation of gemistocytic cells and glial fibrillary acidic protein-(GFAP) positive oligodendroglial cells in gliomas: a MIB1/GFAP double labeling study. Acta Neuropathol (Berl) 91: 99-103
23. Kros JM, van den Brink WA, van Loon-van Luyt JJ, Stefanko SZ 1997 Signet-ring cell oligodendroglioma: report of two cases and discussion of the differential diagnosis. Acta Neuropathol (Berl) 93: 638-643
24. Lantos PL, VandenBerg SR, Kleihues P 1997 Tumours, of nervous system. In: Graham DI, Lantos PL (eds) Greenfield's Neuropathology, 6th edn. Arnold, London, pp 627-636
25. Ludwig CL, Smith MT, Godfrey AD, Armbrustmacher VW 1986 A clinicopathological study of 323 patients with oligodendrogliomas. Ann Neurol 19: 15-21
26. Mork SJ, Halvorsen TB, Lindegaard KF, Eide GE 1986 Oligodendroglioma. Histologic evaluation and prognosis. J Neuropathol Exp Neurol 45: 65-78
27. Mork SJ, Lindeguard KF, Halvorsen TB, Lehmann EH, Solguard T, Hatlevoll R, Harvei S, Ganz J 1985 Oligodendroglioma: incidence and biological behavior in a defined population. J Neurosurg 63: 881-889
28. Nakagawa Y, Perentes E, Rubinstein LJ 1986 Immunohistochemical characterization of oligodendrogliomas: an analysis of multiple markers. Acta Neuropathol (Berl) 72: 15-22
29. Ohgaki H, Schauble B, zur Hausen A, von Ammon K, Kleihues P 1995 Genetic alterations associated with the evolution and progression of astrocytic brain tumors. Virchows Arch 427: 113-118
30. Paveric J, Hlavka V, Poljak M, Gale N, Paveric K 1994 p53 immunoreactivity in oligodendrogliomas. J Neurooncol 22: 1-6
31. Peterson K, Paleologos N, Forsyth P, Macdonald DR, Cairncross JG 1996 Salvage chemotherapy for oligodendroglioma. J Neurosurg 85: 597-601
32. Raff MC, Miller RH, Noble M 1983 A glial progenitor cell that develops in vitro into an astrocyte or an oligodendrocyte depending on culture medium. Nature 303: 390-396
33. Reifenberger J, Reifenberger G, Liu L, James CD, Wechsler W, Collins VP 1994 Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p. Am J Pathol 145: 1175-1190
34. Schiffer D, Giordana MT, Dutto A, Chio A, Cavalla P 1996 Oligoastrocytomas: definition and prognosis. Clin Neuropathol 15: 292-293
35. Shaw EG, Scheithauer BW, O'Fallon JR, Davis DH 1994 Mixed oligoastrocytomas: A survival and prognostic factor analysis. Neurosurgery 34: 577-582
36. Shimada Y, Kubo O, Tajika K Hiyama H, Atuji S, Takokura K 1996 Clinicopathological study of mixed oligoastrocytoma. In: Nagai M (ed) Brain tumor, research and therapy. Springer, Tokyo, pp 51-60
37. Smith MT, Ludwig CL, Godfrey AD, Armbrustmacher VW 1983 Grading of oligodendrogliomas. Cancer 52: 2107-2114
38. Watanabe K, Tachibana O, Sato K, Yonekawa Y, Kleihues P, Ohgaki H 1996 Overexpression of the EOF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas. Brain Pathol 6: 217-224
39. Wondrusch E, Huemer M, Budha H 1991 Production of glial fibrillary acidic protein (GFAP) by neoplastic oligodendrocytes: Gliofibrillary Oligodendroglioma and transitional oligoastrocytoma revisited. Brain Tumor Pathol 8: 11-15